Phase 3 Clinical Trials With Primary Completion Dates in May 2024
This is a list of Phase 3 trials with primary completion dates in May 2024 for companies with a market cap less than $1B. For complete clinical trial coverage, please see our Trial Tracker tool. It includes information on all clinical trials for publicly traded companies, screenable by stock symbol, market cap, disease, completion date, and phase.
The primary completion date is the date that the final subject was examined or received an intervention for the purposes of final collection of data for the primary outcome. It provides advance notice that a company will be announcing trial results in the near future.
| Symbol | Company | Primary Completion Date | Phase | NCT ID | Title |
|---|---|---|---|---|---|
| AGIO | Agios Pharmaceuticals, Inc. | 2024-05-01 | Phase 3 | NCT05144256 | A Study to Evaluate the Efficacy and Safety of Mitapivat in Pediatric Participants With Pyruvate Kinase Deficiency (PKD) Who Are Regularly Transfused, Followed by a 5-Year Extension Period |
| ALVO | Alvotech | 2024-05-01 | Phase 3 | NCT05986786 | Clinical Study to Evaluate the Handling and Safety of AVT06 PFS in Subjects With Chorioretinal Vascular Disease |
| GRFS | Grifols, S.A. | 2024-05-01 | Phase 3 | NCT03451292 | Effects of Long-Term Administration of Human Albumin in Subjects With Decompensated Cirrhosis and Ascites |
| ITCI | Intra-Cellular Therapies, Inc. | 2024-05-01 | Phase 3 | NCT05061719 | An Open-label Study of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder |
| ITCI | Intra-Cellular Therapies, Inc. | 2024-05-01 | Phase 3 | NCT05061706 | Multicenter Study of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder |